<SEC-DOCUMENT>0000950170-25-023729.txt : 20250220
<SEC-HEADER>0000950170-25-023729.hdr.sgml : 20250220
<ACCEPTANCE-DATETIME>20250220070008
ACCESSION NUMBER:		0000950170-25-023729
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250219
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250220
DATE AS OF CHANGE:		20250220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		25643217

	BUSINESS ADDRESS:	
		STREET 1:		350 BAY STREET
		STREET 2:		SUITE 100 #6009
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94133
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		350 BAY STREET
		STREET 2:		SUITE 100 #6009
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94133
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>fgen-20250219.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-20T01:42:59.7395+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:fgen="http://www.fibrogen.com/20250219" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_0fdb8ec3-9c5b-43f9-ab63-c89c2d6b1786" name="dei:AmendmentFlag" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d">false</ix:nonNumeric><ix:nonNumeric id="F_eff2edba-3707-40ab-b81d-e323ab7b622b" name="dei:EntityCentralIndexKey" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d">0000921299</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="fgen-20250219.xsd"/></ix:references><ix:resources><xbrli:context id="C_0355883d-0e56-47d9-b893-a645298c816d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-19</xbrli:startDate><xbrli:endDate>2025-02-19</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bec0af1e-a2e8-462f-b223-a36aac16d259" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_12c0d174-796f-4399-a867-2a31d77839c9" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">February 19, 2025</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1018481c-f2c3-4e85-aefe-cd7dafdbd914" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FIBROGEN, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:18%;box-sizing:content-box;"/>
    <td style="width:41%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0c1d0bb0-3b05-4023-b819-0526b3572d37" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9413a325-8344-4e46-aa92-0c830d10ca10" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-36740</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_913fc160-97bd-4a71-bcd3-51967ef5e6b7" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">77-0357827</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d1ef245f-d96f-4e32-8ba3-c134051cb0a4" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">350 Bay Street</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c5fb1dcb-c506-4fab-a82b-5f2de714add8" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 100 #6009 </span></ix:nonNumeric></span><span></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6c77dcfe-649f-4dde-82cd-60debca7579b" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">San Francisco</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_0a2041a9-d5ed-4663-b26c-57f6b0cfcd63" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_160d9d8d-cbe8-4a0d-9b8b-a7b1bbee1a2e" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">94133</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_0cc47789-06bf-4dfb-89c3-0d026548fabc" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">415</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_b2051cee-f474-4342-ae80-412c57ed49d2" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">978-1200 </span></ix:nonNumeric></span><span></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00e9ceb0-1978-44f0-b791-f2fd7fa4c855" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_210f5e97-8cd0-42a3-a6de-6d594fc225f2" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73739c78-794a-46af-8670-23ff02ec97fc" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2319e3f-0fa9-4f52-8159-b7d13f008279" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_27d2b0ca-9d97-4de2-8db9-e7f5056d8138" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.01 par value</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8f9086a0-6c5f-4e11-89e8-3f911b580825" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FGEN</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_55197e0c-0254-41b0-9d3e-db609be76382" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_82b1aa3c-ebca-42c2-be17-3fd938aa9358" contextRef="C_0355883d-0e56-47d9-b893-a645298c816d" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1.01	Entry into a Material Definitive Agreement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 19, 2025, FibroGen, Inc. (the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;,  &#8220;our&#8221;, or &#8220;FibroGen&#8221;) entered into a share purchase agreement (the &#8220;Share Purchase Agreement&#8221;) with AstraZeneca Treasury Limited (&#8220;AstraZeneca&#8221;) pursuant to which we and our indirect subsidiary FibroGen China Anemia Holdings, Ltd. agreed to sell all of the issued and outstanding equity interests of FibroGen International (Hong Kong) Ltd. (&#8220;FibroGen International&#8221;) to AstraZeneca for an aggregate purchase price of approximately $160 million, comprised of $85 million in cash for the enterprise value of FibroGen International, plus an additional cash amount equal to the net cash held in China by FibroGen International and its subsidiaries, currently anticipated to be approximately $75 million, as of the closing. The transaction is expected to close by mid-2025, and is subject to customary closing conditions and closing deliverables, including receipt of regulatory approval from the China State Administration for Market Regulation. At the closing, we intend to repay our term loan facility with Morgan Stanley Tactical Value (approximately $80 million in total).  The facility is filed as Exhibit 10.5 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed with the Securities and Exchange Commission on August 7, 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AstraZeneca is our long-time commercialization partner for roxadustat in greater China and South Korea.  Upon the closing, AstraZeneca will acquire all the rights to roxadustat in China, Hong Kong, and Macao, including rights to manufacture, develop, distribute, and commercialize roxadustat.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will retain the rights to roxadustat in the United States, Canada, Mexico, and in all markets not held by AstraZeneca or licensed to Astellas Pharma Inc. Astellas is commercializing roxadustat (Evrenzo</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) in Europe and Japan to treat anemia under two development and commercialization license agreements: one for Japan, and one for Europe, the Commonwealth of Independent States, the Middle East and South Africa.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net cash payable by AstraZeneca at the closing is subject to holdbacks of: (i) a $6.0 million hold back to offset final net cash adjustments which will be released following a customary adjustment process approximately 90 days post-closing (as such time may be extended for the parties to mutually agree upon final adjustments), and (ii) a $4.0 million hold back to satisfy any indemnity claims, which will be released, net of any claims paid or unresolved, nine months after the closing.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Share Purchase Agreement includes customary representations and warranties, including fundamental representations and regulatory compliance provisions and other provisions relating to FibroGen International&#8217;s and its subsidiaries&#8217; business. The representations, warranties, and covenants contained in the Share Purchase Agreement were made only for purposes of such agreement and as of specific dates, and were solely for the benefit of the parties to such agreement. The Share Purchase Agreement contains other customary provisions for transactions of this nature.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Share Purchase Agreement AstraZeneca will purchase all of the issued and outstanding equity interests of FibroGen International from FibroGen China Anemia Holdings, Ltd.  FibroGen International wholly owns FibroGen (China) Medical Technology Development Co., Ltd. which holds, among other assets, the roxadustat drug product manufacturing facility, roxadustat inventory and supply relationships, and 51.1% of Beijing Falikang Pharmaceutical Co., Ltd. (the roxadustat distribution joint venture currently owned 48.9% by AstraZeneca). On closing, FibroGen will assign to FibroGen International its entire right, title, and interest to certain patents, trademarks, and domain name registration related to FibroGen's roxadustat business in China, Hong Kong, and Macao.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AstraZeneca is purchasing certain transition support services from us to support the businesses of the in-scope companies (FibroGen International and its subsidiaries) pursuant to a transitional services agreement, which services will be provided for a maximum of 12 months post-closing.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing description of the Share Purchase Agreement is only a summary of the terms of, and is qualified in its entirety by reference to the full text of, the Share Purchase Agreement, which will be filed as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. The approximately $75 million of cash held in China is only an estimate and could change materially before closing. We do not intend to update this estimate prior to closing and undue reliance should not be placed on this preliminary estimate.  In addition, the total amount to be paid to Morgan Stanley Tactical Value is only our best estimate and includes principal, accrued and unpaid interest, and an applicable prepayment penalty, and could change materially before this term loan facility is paid off.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2.02.	Results of Operations and Financial Condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 20, 2025, we announced that as of December 31, 2024, we estimated that we had approximately $121.1 million in cash, cash equivalents, and accounts receivable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This preliminary financial information is unaudited and is based on currently available information and does not present all necessary information for an understanding of our financial condition as of December 31, 2024 or our results of operations for the year ended December 31, 2024. This preliminary financial information has been prepared by, and is the responsibility of, our management. It is possible that we may identify items that require us to make adjustments to the financial information set forth above and those changes could be material. We do not intend to update this estimate prior to completion of our year-end audited financial statements. Accordingly, undue reliance should not be placed on this preliminary estimate and this estimate is not necessarily indicative of any future period.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in this Item 2.02 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by FibroGen, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5.02	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the closing of the sale of FibroGen International pursuant to the Share Purchase Agreement, Christine L. Chung, who currently serves as our Senior Vice President, China Operations, will cease employment with us.  Ms. Chung is entitled to certain severance benefits pursuant to our executive officer change in control and severance agreement, which is filed as Exhibit 10.4 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed with the Securities and Exchange Commission on May 8, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7.01.	Regulation FD Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A copy of the press release announcing the sale of FibroGen International pursuant to the Share Purchase Agreement and our estimated cash and cash equivalents as of December 31, 2024, is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in Exhibit 99.1 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in Exhibit 99.1 shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by FibroGen, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">           (d)    Exhibits</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.198%;box-sizing:content-box;"/>
    <td style="width:1.04%;box-sizing:content-box;"/>
    <td style="width:86.763%;box-sizing:content-box;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.75pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.75pt solid #ffffff03;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.75pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="fgen-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release dated February 20, 2025.</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:44%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:46%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FIBROGEN, INC.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 20, 2025</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ John Alden</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">John Alden<br/>General Counsel</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>fgen-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img3914235_0.jpg" alt="img3914235_0.jpg" style="width:178px;height:45px;"></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FibroGen Announces the Sale of FibroGen China to AstraZeneca for </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approximately $160 Million</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 million</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Upon close, FibroGen will repay its term loan to Morgan Stanley Tactical Value, further simplifying the Company&#x2019;s capital structure</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company&#x2019;s cash runway extended into 2027</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company to continue to advance its oncology pipeline, with the initiation of the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) in 2Q 2025</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preliminary unaudited cash, cash equivalents, and accounts receivable of $121.1 million as of December 31, 2024</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FibroGen to host conference call and webcast presentation today at 8:30 AM ET</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SAN FRANCISCO, February 20, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the sale of its China subsidiary to AstraZeneca for approximately $160 million.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Today, we announced the sale of FibroGen China to AstraZeneca, our long-time strategic partner for roxadustat in China, bolstering our company on several fronts. It strengthens our financial position, meaningfully extending our cash runway into 2027, and enables us to continue progressing the clinical development program for FG-3246, our first-in-class, CD46 targeting antibody drug conjugate, and FG-3180, our companion PET imaging agent, in mCRPC,&#x201d; said Thane Wettig, Chief Executive Officer of FibroGen. &#x201c;After a thorough evaluation of alternatives, we believe selling our China operations and repaying our term loan is in the best interest of FibroGen&#x2019;s stakeholders. We are grateful for our China colleagues, and in particular Christine Chung, our Head of China Operations, for their unwavering commitment to patients and successful commercialization of roxadustat in China. Now, we turn the page to the next exciting chapter for FibroGen.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the agreement, FibroGen will receive an enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 million, totaling approximately $160 million. The transaction is expected to close by mid-2025, pending customary closing conditions, including regulatory review in China. Following the close of the transaction, FibroGen will repay its term loan facility to investment funds managed by Morgan Stanley Tactical Value, further simplifying the Company&#x2019;s capital structure. The combined transactions are expected to extend the Company&#x2019;s cash runway into 2027.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon closing, AstraZeneca will obtain all rights to roxadustat in China. Roxadustat is the category leader in brand value share for the treatment of anemia in chronic kidney disease with a pending regulatory decision for chemotherapy-induced anemia.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FibroGen maintains its rights to roxadustat in the U.S. and in all markets not licensed to Astellas.  The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS), a high-value indication with significant unmet medical need.  The Company is planning for an FDA meeting in the second quarter of 2025 to determine the potential next steps for the development program for roxadustat in the U.S.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, FibroGen continues to advance the clinical development of its lead asset, FG-3246, and its companion PET imaging agent, FG-3180, with the initiation of the Phase 2 monotherapy trial of FG-3246 in patients with mCRPC expected in the second quarter of 2025.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BofA Securities, Inc. is acting as exclusive financial advisor and Ropes &amp; Gray LLP is acting as legal advisor to FibroGen on this transaction.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conference Call and Webcast Presentation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FibroGen management team will host a conference call and webcast presentation today, February 20, 2025 at 8:30 a.m. ET to discuss the sale of FibroGen China. A live Q&amp;A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">here</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. To access the call by phone, please </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">register here</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Events &amp; Presentations</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> page on FibroGen&#x2019;s website.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">About FibroGen</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (&#x7231;&#x745e;&#x5353;&#174;, EVRENZO</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">www.fibrogen.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This release contains forward-looking statements regarding FibroGen&#x2019;s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its collaboration partners Fortis and UCSF. These forward-looking statements include, but are not limited to, statements regarding the net cash portion of the purchase price and closing of the sale of FibroGen China as well as the payoff of the Morgan Stanley Tactical Value term loan, use of proceeds, and statements regarding the expectation that cash, cash equivalents and accounts receivable will be sufficient to fund FibroGen&#x2019;s operating plans into 2027, and statements about FibroGen&#x2019;s plans and objectives. These forward-looking statements are typically identified by use of terms such as &#x201c;may,&#x201d; &#x201c;will&#x201d;, &#x201c;should,&#x201d; &#x201c;on track,&#x201d; &#x201c;could,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;predict,&#x201d; &#x201c;potential,&#x201d; &#x201c;continue&#x201d; and similar words, although some forward-looking statements are expressed differently. FibroGen&#x2019;s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img3914235_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img3914235_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !G 9@# 2(  A$! Q$!_\0
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M<OS$<X'I5JSW.>I.I'6*N>LMTKSN:TU+0-8UK5?"\/\ :5JLB1W&A>?L5I
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M8H^WW(Y,1*DYCC(PPSAG&,D YY*Z^,'_  D6I6?@_6K2?P9?79:._GN)P$
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MU4S1N%?FE^Q3X\^+WQ0^,UI#)XYUN_\ #]@GVG5A?W)N(C$#Q& ^<%VP,C!
MR:]I_:>_;RM/AEJUYX6\#P6^L^(8,QW6HS'=;6C]T4 _/(._8'@YY%9RP\U/
MV:U9:JQY>9GV)NI-U?C?XF_:V^+WBJ[$\_CO5K,KG$>ER?9$Y/<1XS^-='X#
M_;F^+G@F: 2Z^/$=E$</;:S&)6<9[R#Y_P <UM]2J6T9"Q$3];J@NKN&RMYK
MBXE6&"%#)))(=JHH&22>P KR3]G3]I+P]^T+X;DNM/4Z=K=J!]NTF1]SPY.
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M'ZKD<94U^G/[*?Q%G^)G[-.CZA=DM?V=I+IURQ!PSQ*55@2><ILR?7-?%O\
MP4:UBRU3]H**WM)4EFL-(@M[G8>4DWR.$/H0KJ?^!5]+_P#!/NWDA_9AO'<D
MK+?WC(#V&Q1_,5ZE>\Z$)RW..G[M221^8]O;R74T<$*&2:601HH&<L3@"OU6
M^ _[%'@/X>>#[,>(]!L?%/B.XB66\N=3@6:.-V )CC1A@*IX!QD\\\X'YA^
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M"1K&S,S=  #DUYL:DXRYKZG5*,6K6/Q=^ OQ-O?@[\6] \10?*D%R+>\@D)
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M2W]Q+)A3*R!B,X''0=J_*+XF6-OI?Q&\5V5K$MO:V^J7444,8PL:"5@J@>P
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1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>fgen-20250219.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-20T01:43:00.0187+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.fibrogen.com/20250219" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:fgen="http://www.fibrogen.com/20250219" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="fgen-20250219.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094038066208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 19, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 19,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FIBROGEN, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000921299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0357827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">350 Bay Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100 #6009 <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">978-1200 <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FGEN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;
M 4/2='@//GL?)=-[*CG_5U/\!%!+ P04    "  #.%1:EXJ[',     3 @
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MB^$_7G\!4$L! A0#%     @  SA46@=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  #.%1:4UO+#^X
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M<W1Y;&5S+GAM;%!+ 0(4 Q0    (  ,X5%J7BKL<P    !,"   +
M      "  8L/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  ,X5%HZJJ+G0 $
M #P"   /              "  700  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    "  #.%1:)!Z;HJT   #X 0  &@              @ 'A$0  >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  #.%1:99!YDAD!  #/
M P  $P              @ '&$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    "0 ) #X"   0%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="fgen-20250219.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="fgen-20250219.htm">fgen-20250219.htm</File>
    <File>fgen-20250219.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "fgen-20250219.htm": {
   "nsprefix": "fgen",
   "nsuri": "http://www.fibrogen.com/20250219",
   "dts": {
    "inline": {
     "local": [
      "fgen-20250219.htm"
     ]
    },
    "schema": {
     "local": [
      "fgen-20250219.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_0355883d-0e56-47d9-b893-a645298c816d",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fgen-20250219.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0355883d-0e56-47d9-b893-a645298c816d",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fgen-20250219.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.fibrogen.com/20250219/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-25-023729-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-023729-xbrl.zip
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M#8)?P=AQ+*)(#,E!&+/8#UE$SJI1-V&:?HOL1!$YQ<\R<BHRD5X*WE*=]G*
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M7XA @R5SEW<X]3TLL&8:IZ[7 =O"\73/$T)GAE@HNWQ)@!^B_X8#F4-Z3E[
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MAXH5+RI,:'C4F/.@^LF^,7(X^KS1>VN9(J>3Y0-/>YO#,M'B_@RZNN,F%IS
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M'KQFC3G!!_5L:@U2&6#UF\H2JS.H,B0,+ LF9M&752%&97$UC<RW3ATR"ID
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M<#US@NM&(A:S0H_)>JWR1U7^Z,GS?N^VO(0//_S]W58O[T<?_A]02P,$%
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M<@9>2$B "1AHZ:-2D6GP0FI\5%XO K=\/1EC83<A(1CPT0"#*Y^_U&W8386
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MD>^/0F"._1++/#\*F4G3)M;VVU%H6^/ZQ'(_'(7<K$<4ZSOT:>H:@RD6^O'
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M562>=*(DQ\,WOFQ.UL&:?ZH36F^<&9!,:+9NW[P*S@3&UYV33L7I"?J8Z9G
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M,C$Y+FAT;5!+ 0(4 Q0    (  ,X5%I7NCB\@0@  !UA   1
M  "  6(>  !F9V5N+3(P,C4P,C$Y+GAS9%!+ 0(4 Q0    (  ,X5%HOU':?
M80\  .)8   /              "  1(G  !F9V5N+65X.3E?,2YH=&U02P4&
2      ,  P"[    H#8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>fgen-20250219_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="fgen-20250219.xsd" xlink:type="simple"/>
    <context id="C_0355883d-0e56-47d9-b893-a645298c816d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2025-02-19</startDate>
            <endDate>2025-02-19</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_0fdb8ec3-9c5b-43f9-ab63-c89c2d6b1786">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_eff2edba-3707-40ab-b81d-e323ab7b622b">0000921299</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_bec0af1e-a2e8-462f-b223-a36aac16d259">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_12c0d174-796f-4399-a867-2a31d77839c9">2025-02-19</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_1018481c-f2c3-4e85-aefe-cd7dafdbd914">FIBROGEN, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_0c1d0bb0-3b05-4023-b819-0526b3572d37">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_9413a325-8344-4e46-aa92-0c830d10ca10">001-36740</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_913fc160-97bd-4a71-bcd3-51967ef5e6b7">77-0357827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_d1ef245f-d96f-4e32-8ba3-c134051cb0a4">350 Bay Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_c5fb1dcb-c506-4fab-a82b-5f2de714add8">Suite 100 #6009 </dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_6c77dcfe-649f-4dde-82cd-60debca7579b">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_0a2041a9-d5ed-4663-b26c-57f6b0cfcd63">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_160d9d8d-cbe8-4a0d-9b8b-a7b1bbee1a2e">94133</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_0cc47789-06bf-4dfb-89c3-0d026548fabc">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_b2051cee-f474-4342-ae80-412c57ed49d2">978-1200 </dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_00e9ceb0-1978-44f0-b791-f2fd7fa4c855">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_210f5e97-8cd0-42a3-a6de-6d594fc225f2">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_73739c78-794a-46af-8670-23ff02ec97fc">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_d2319e3f-0fa9-4f52-8159-b7d13f008279">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_27d2b0ca-9d97-4de2-8db9-e7f5056d8138">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_8f9086a0-6c5f-4e11-89e8-3f911b580825">FGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_55197e0c-0254-41b0-9d3e-db609be76382">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_0355883d-0e56-47d9-b893-a645298c816d"
      id="F_82b1aa3c-ebca-42c2-be17-3fd938aa9358">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
